srf388
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 22, 2020 (NCT04374877)
Timeline
Indications
Mechanism of action
- Interleukin-27 subunit alphaINHIBITOR
IL27 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314661 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06679985 | Phase 2 | Nov 30, 2024 | Coherus BioSciences |
| NCT05359861 | Phase 2 | Apr 12, 2022 | Surface Oncology |
| NCT04374877 | Phase 1 | Apr 22, 2020 | Surface Oncology |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Surface Oncology | For profit | 2 | 2 | 2 | 2020 |
| Coherus BioSciences | For profit | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1